Advanced Breast Cancer Archives - Page 2 of 8

FDA 2015 Drug Approvals Encompass Wide Range of Cancer Types

By

Debra Hughes, MS

January 11, 2016

The year 2015 brought treatment advances for patients with myriad cancer types, as reflected in U.S. Food and Drug administration approvals.

Breast Cancer

Blood Test Aids in Identifying Treatment Resistance in Metastatic Breast Cancer

By

Nicole Ostrow

November 30, 2015

A new sensitized blood test can help clinicians discover when breast cancers become resistant to standard hormone therapy.

Pre- or postmenopausal women with epithelial ovarian cancer can safely be treated with adjuvant horm

Breast Cancer

Low-dose Estradiol Effective in Certain Patients With Advanced Breast Cancer

By

Jason Hoffman, PharmD, RPh

November 20, 2015

Low-dose estradiol is an effective and well tolerated endocrine option in postmenopausal women with advanced breast cancer.

KRAS mutational status does not seem to influence the outcome of maintenance treatment with erlotini

Breast Cancer

Everolimus Efficacy Independent of Genetic Alterations in EGFR2-negative Breast Cancer

By

Lourdes Briz

October 27, 2015

An exploratory analysis revealed that the efficacy of everolimus was independent of the most commonly altered genes in breast cancer.

Breast Cancer

American Cancer Society Updates Breast Cancer Screening Guidelines

By

Jason Hoffman, PharmD, RPh

October 20, 2015

For the first time in a decade, the American Cancer Society has updated its breast screening guidelines.

GEMOXEL regimen may be safe, more efficient than standard therapy for metastatic pancreatic cancer.

Breast Cancer

Etirinotecan Pegol Fails to Improve Survival in Heavily Pre-treated Breast Cancer

By

Jason Hoffman, PharmD, RPh

October 19, 2015

Etirinotecan pegol did not significantly improve overall survival in patients with heavily pre-treated advanced breast cancer.

Breast Cancer

Women in Certain Racial Groups At Higher Risk for Advanced Breast Cancer

October 15, 2015

Women in certain racial/ethnic groups are more likely to be diagnosed with more advanced breast cancer.

High tumor expression of ANXA1 could be predictive of trastuzumab resistance in patients with HER-2

Breast Cancer

ANXA1 Identified as Potential Predictor of Trastuzumab Resistance

By

Andrea S. Blevins Primeau, PhD, MBA

September 23, 2015

High tumor expression of ANXA1 could be predictive of trastuzumab resistance in patients with HER-2 positive breast cancer.

Breast Cancer

Women With Mucinous, Tubular/Cribriform Breast Cancer Fare Better Than Other Histotypes

By

Lourdes Briz

September 21, 2015

Women with mucinous or tubular/cribriform breast cancer had better outcomes than those with other histotypes.

Breast Cancer

First-Line Fulvestrant May Prolong Survival in Advanced Breast Cancer

By

Jason Hoffman, PharmD, RPh

September 15, 2015

Fulvestrant 500 mg may extend overall survival compared with anastrozole 1 mg as first-line endocrine therapy for advanced breast cancer.